论文部分内容阅读
目的：探讨红细胞生成素（EPO）对恶性肿瘤贫血的疗效、用药剂量及时间。方法：对36例癌症贫血患者采用皮下注射EPO，开始剂量2000IU／次，2次／周，1个月后根据患者HCT水平调整EPO剂量，当HCT达到目标位（30％）后剂量减半，持续观察2周。结果：治疗前后患者HCT、Hb、RBC值比较均有显著增高，P值＜0．05，平均EPO用量为7021±25．26IU／kg／W。结论：EPO纠正恶性肿瘤患者因放疗、化疗造成的骨髓抑制性贫血，其疗效肯定，且皮下给药可取得与静脉给药相同的结果。
Objective: To investigate the efficacy, dose and time of erythropoietin (EPO) in anemia of malignant tumors. METHODS: Thirty-six patients with anemia of cancer were treated with subcutaneous EPO at a dose of 2000 IU/time, 2 times/week. One month later, the dose of EPO was adjusted according to the patient’s HCT level. When the HCT reached the target level (30%), the dose was halved. Keep watching for 2 weeks. Results: The values of HCT, Hb, and RBC were significantly increased before and after treatment. The P value was <0.05, and the average EPO dosage was 7021±25.26 IU/kg/W. CONCLUSIONS: EPO corrects patients with malignant tumors due to bone marrow suppression anemia caused by radiotherapy and chemotherapy. Its efficacy is positive, and subcutaneous administration can achieve the same results as intravenous administration.